Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

859 results
Display

Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway

Masraksa W, Tanasawet , Hutamekalin P, Wongtawatchai T, Sukketsiri W

BACKGROUND/OBJECTIVES: Non-small cell lung cancer is mostly recognized among other types of lung cancer with a poor prognosis by cause of chemotherapeutic resistance and increased metastasis. Luteolin has been found...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Lim SM, Hong MH, Kim HR

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Performances of CYFRA 21-1, Carcinoembryonic Antigen and Their Combination for Lung Cancer Diagnosis

Kim JJ, Ahn HJ, Park Y

BACKGROUND: The aim of this study was to compare the efficiency of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) for the diagnosis of lung cancer and to establish...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma

Kim T, Cha YJ, Chang YS

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is tested by immunohistochemistry (IHC)—22C3, SP263, and SP142. The aim of this study is to evaluate the correlation among the three methods of PD-L1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemoradiotherapy versus radiotherapy alone following induction chemotherapy for elderly patients with stage III lung cancer

Kim DY, Song C, Kim SH, Kim YJ, Lee JS, Kim JS

PURPOSE: It is unclear whether adding concurrent chemotherapy (CT) to definitive radiotherapy (RT) following induction CT is a tolerable and cost effective treatment for non-small-cell lung cancer (NSCLC) patients aged...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Park EY, Kim YS, Choi KH, Song JH, Lee HC, Hong SH, Kang JH

PURPOSE: This study aimed to investigate neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors in patients with locally advanced non-small cell lung cancer (NSCLC) who received concurrent chemoradiotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Local ablative radiotherapy for oligometastatic non-small cell lung cancer

Suh YG, Cho J

In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS

BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Preoperative Risk Factors for Pathologic N2 Metastasis in Positron Emission Tomography-Computed Tomography–Diagnosed N0–1 Non-Small Cell Lung Cancer

Yoon TH, Lee CH, Park KS, Bae CH, Cho JW, Jang JS

BACKGROUND: Accurate mediastinal lymph node staging is vital for the optimal therapy and prognostication of patients with lung cancer. This study aimed to determine the preoperative risk factors for pN2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer

Lim TY, Park S, Kang CH

Lobectomy is considered the standard strategy for early-stage non-small cell lung cancer (NSCLC). However, sublobar resection for NSCLC has recently received increased attention. The objective of this study was to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between Expression of 8-OHdG and Cigarette Smoking in Non-small Cell Lung Cancer

An AR, Kim KM, Park HS, Jang KY, Moon WS, Kang MJ, Lee YC, Kim JH, Chae HJ, Chung MJ

BACKGROUND: Exposure to cigarette smoking (CS) is a major risk factor for the development of lung cancer. CS is known to cause oxidative DNA damage and mutation of tumor-related genes,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future

Kim H, Chung JH

Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS

PURPOSE: The purpose of this study was to evaluate the relationships between the resistance of anaplastic lymphoma kinase (ALK)‒positive non-small cell lung cancer (NSCLC) to ALK inhibitors and the programmed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS

PURPOSE: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study

Chung E, Noh JM, Lee KC, Kim JH, Chung WK, Suh YG, Lee JA, Seol KH, Wu HG, Kim YS, Noh OK, Park JW, Lee DS, Lee J, Kim YS, Park WY, Kang MK, Jo S, Ahn YC

PURPOSE: Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS

PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression

Park HY, Oh IJ, Kho BG, Kim TO, Shin HJ, Park CK, Kwon YS, Kim YI, Lim SC, Kim YC, Choi YD

BACKGROUND: Programmed death-ligand 1 (PD-L1), a transmembrane protein, binds to the programmed death-1 (PD-1) receptor, and anti-PD-1 therapy enables immune responses against tumors. This study aimed to assess clinical characteristics...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Choi JH, Choi J, Chung SM, Oh JY, Lee YS, Min KH, Hur GY, Shim JJ, Kang KH, Lee HK, Lee SY

BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Factors in Stage IIB Non-Small Cell Lung Cancer according to the 8th Edition of TNM Staging System

Shin JW, Cho DG, Choi SY, Park JK, Lee KY, Moon Y

BACKGROUND: The purposes of this study were to evaluate the appropriateness of the stage migration of stage IIA non-small cell lung cancer (NSCLC) in the seventh edition of the tumor,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer

Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC

PURPOSE: Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) mutation testing (e.g., for T790M mutations), and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr